Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment, and Lutetium 177Lu-prostate specific-membrane antigen (PSMA)-617 (LuPSMA) in patients with prostate cancer that has progressed despite being previously treated with androgen therapies and has spread from where it first started (prostate) to other places in the body (metastatic castration-resistant prostate cancer). In patients that have developed progressive cancer in spite of standard hormonal treatment, administering supraphys

Trial Details

NCT ID

NCT06039371

Phase

PHASE2

Sponsor

University of Washington

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Bone Scan
Carboplatin
Computed Tomography
Etoposide

Locations (sample)

Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

Must be willing to provide informed consent prior to any study specific procedures
Age \>= 18 years
Documented histologically confirmed adenocarcinoma of the prostate
Patient must have evidence of castration resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 \[PCWG3\] c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →